NKMAX CO., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 03:13 am EDT
Share
NKMAX CO., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 0.00001 million compared to KRW 0.00001 million a year ago. Net loss was KRW 17,274.31 million compared to KRW 17,279.14 million a year ago. Basic loss per share from continuing operations was KRW 214 compared to KRW 219.5 a year ago. Basic loss per share was KRW 214 compared to KRW 219.5 a year ago.
For the six months, sales was KRW 0.00001 million compared to KRW 0.00001 million a year ago. Net loss was KRW 31,216.42 million compared to KRW 30,062.72 million a year ago. Basic loss per share from continuing operations was KRW 389.5 compared to KRW 386 a year ago. Basic loss per share was KRW 389.5 compared to KRW 386 a year ago.
NKMAX Co., Ltd., formerly ATGen, is a Korea-based company principally engaged in the research, development, manufacturing and supply of biological products. The Company is involved in the production and sale of recombinant proteins, monoclonal antibodies, NK cell activity test kits, cell therapy products, and in the provision of other related services. The NK cell activity test kits are provided under the name of NK Vue. The Company distributes its products within domestic market and to overseas markets.
NKMAX CO., LTD. 
